ACST Stock – (NASDAQ: ACST) is actually giving an update on the use
ACST Stock – (NASDAQ: ACST) is providing an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually providing an update on the usage of the “at-the market” equity of its providing plan.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering program under which Acasti may issue and market from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January 27, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares ended up being marketed at prevailing market rates averaging US$1.0747 per share. No securities had been sold in the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and will provide the Company with additional flexibility in its ongoing review process to check out and evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescribed drugs making use of OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of efficacy as well as safety in lowering triglycerides in people with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for people with severe HTG.
Forward Looking Statements – ACST Stock
Statements in that press release which are not statements of current or historical fact constitute “forward-looking information” to the meaning of Canadian securities laws and “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking statements include known and unknown risks, uncertainties, as well as other unknown elements that might cause the actual outcomes of Acasti to be materially different from historical success or as a result of any future outcomes expressed or implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, people are urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be forward-looking and uncertain. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the date of this press release. Forward-looking statements in that press release include, but aren’t restricted to, statements or info about Acasti’s strategy, future operations as well as the review of its of strategic options.
The forward-looking statements found in this specific press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” section in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor aisle of Acasti’s website at www.acastipharma.com. Most forward looking assertions in that press release are available as of the date of this press release.
ACST Stock – Acasti does not undertake to redesign any such forward looking statements whether as a direct result of information which is new, future events or otherwise, except as needed by law. The forward looking assertions contained herein are also subject typically to risks and assumptions and uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the use